初诊大肿块弥漫性大B细胞淋巴瘤患者临床特征及预后分析  

Clinical characteristics and prognosis of newly diagnosed diffuse large B-cell lymphoma with bulky mass

作　　者：王妍杰 张旭东[1] 葛晶晶 刘栋林 马珊珊[1] 张文君[1] 陈清江[1] Yanjie Wang;Xudong Zhang;Jingjing Ge;Donglin Liu;Shanshan Ma;Wenjun Zhang;Qingjiang Chen(Department of Oncology,The First Affiliated Hospital of Zhengzhou University,Henan Province Lymphoma Treatment Center,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,河南省淋巴瘤诊疗中心,郑州市450052

出　　处：《中国肿瘤临床》2023年第7期345-351,共7页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:82070210);河南省医学科技攻关重大项目(编号:SBGJ202001008)资助。

摘　　要：目的:分析初诊时伴有大肿块的弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者的临床特征与预后因素。方法:回顾性分析2018年1月至2021年9月郑州大学第一附属医院收治的194例大肿块DLBCL患者的临床资料,其中大肿块定义为肿瘤最大直径(maximum tumor diameter,MTD)≥7.5 cm,根据大肿块所在部位将患者分为:腹盆腔组、胸腔组、头颈部组。结果:194例大肿块DLBCL患者中位总生存(median overall survival,mOS)期为16(0~50)个月,患者1、3年总生存(overall survival,OS)率分别为75.6%、66.2%。1、3年无进展生存(progression-free survival,PFS)率分别为55.9%和44.1%。患者一线治疗后达到完全缓解(complete response,CR)、部分缓解(partial response,PR)、疾病稳定(stable disease,SD)、疾病进展(progressive disease,PD)分别为45例(23.2%)、78例(40.2%)、11例(5.7%)、60例(30.9%),一线治疗客观缓解率(overall response rate,ORR)为63.4%。单因素分析结果显示,年龄、Ann Arbor分期、β2-微球蛋白水平(β2-microglobulin,β2-MG)、有无中枢侵犯、是否放疗、大肿块所在部位是影响大肿块DLBCL患者OS的预后因素(P<0.05);Cox回归模型多因素分析结果显示,年龄>60岁、Ann Arbor分期Ⅲ/Ⅳ期、大肿块所在部位为腹盆腔组、头颈部组是大肿块DLBCL的独立不良预后因素(P<0.05)。腹盆腔组患者分期较晚、B症状多见、β2-微球蛋白水平多升高、C反应蛋白水平较高、Ki-67值较高;胸腔组年轻患者比例较高、临床分期较早、非GCB亚型更多见。腹盆腔组、胸腔组、头颈部组3组患者的3年OS率分别为60.4%、84.4%和54.2%,差异具有统计学意义(P<0.01)。结论:大肿块DLBCL患者肿瘤负荷高,一线治疗缓解率低、疾病进展率高,年龄>60岁、临床分期晚、大肿块所在腹盆腔组和头颈部组的患者预后较差。Objective:To analyze the clinical characteristics and prognostic factors of patients with diffuse large B-cell lymphoma(DLBCL)with bulky mass at initial diagnosis.Methods:We retrospectively analyzed the clinical data of 194 patients with DLBCL with bulky mass admitted to The First Affiliated Hospital of Zhengzhou University from January 2018 to September 2021.Bulky mass was defined as a maximum tumor diameter(MTD)≥7.5 cm.The patients were assigned into three groups,the abdominopelvic,thoracic cavity,and head and neck groups,according to the location of bulky mass.Results:The median overall survival(OS)of 194 patients with DLBCL with bulky mass was 16(range,0–50)months,while the 1-year and 3-year OS rates were 75.6%and 66.2%,respectively.The 1-year and 3-year progression-free survival(PFS)rates were 55.9%and 44.1%,respectively.Following the first-line treatment,complete response(CR),partial response(PR),stable disease(SD),and progressive disease(PD)were achieved in 45(23.2%),78(40.2%),11(5.7%)and 60 cases(30.9%),respectively.The objective response rate(ORR)of the first-line treatment was 63.4%.Univariate analysis revealed that the prognostic factors affecting OS included age,Ann Arbor stage,β2-microglobulin(β2-MG),central invasion,radiotherapy,and bulky mass location(P<0.05).Multivariate analysis using Cox regression model revealed that age>60 years,Ann Arbor stageⅢ/Ⅳ,bulky mass located in the abdominopelvic and head and neck regions were independent prognostic factors(P<0.05).Patients in the abdominopelvic group had a more advanced clinical stage,more symptoms of B,an increasedβ2-MG level,a higher C-reactive protein level,and a higher Ki-67 value,while the thoracic cavity group had a higher proportion of young patients,a less advanced clinical stage,and more non-GCB subtypes.The 3-year OS rates of patients in the abdominopelvic,thoracic cavity,and head and neck groups were 60.4%,84.4%and 54.2%,respectively,with statistical differences(P<0.01).Conclusions:Patients with DLBCL with bulky mass have a high

关 键 词：弥漫性大B细胞淋巴瘤 大肿块 临床特征 预后分析 肿瘤部位 

分 类 号：R733.1[医药卫生—肿瘤]